SAB Biotherapeutics Valuation
| SABSW Stock | USD 0.03 0.0001 0.40% |
SAB Biotherapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of SAB Biotherapeutics from examining the entity fundamentals such as Return On Asset of -0.79, gross profit of (25.38 M), and Number Of Shares Shorted of 1.18 K as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting SAB Biotherapeutics' valuation include:
Trailing PE 0.0856 |
Overvalued
Today
Please note that SAB Biotherapeutics' price fluctuation is out of control at this time. Calculation of the real value of SAB Biotherapeutics is based on 3 months time horizon. Increasing SAB Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the SAB stock is determined by what a typical buyer is willing to pay for full or partial control of SAB Biotherapeutics. Since SAB Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of SAB Stock. However, SAB Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.025 | Real 0.0205 | Hype 0.03 |
The intrinsic value of SAB Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence SAB Biotherapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of SAB Biotherapeutics helps investors to forecast how SAB stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of SAB Biotherapeutics more accurately as focusing exclusively on SAB Biotherapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use SAB Biotherapeutics' intrinsic value based on its ongoing forecasts of SAB Biotherapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against SAB Biotherapeutics' closest peers.
SAB Biotherapeutics Cash |
|
SAB Valuation Trend
Analysing the historical paterns of SAB Biotherapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of SAB Biotherapeutics over time and is usually enough for investors to make rational market timing decisions.
SAB Biotherapeutics Total Value Analysis
SAB Biotherapeutics is at this time projected to have takeover price of 0 with market capitalization of 0, debt of 5.91 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the SAB Biotherapeutics fundamentals before making investing decisions based on enterprise value of the companySAB Biotherapeutics Investor Information
The company had not issued any dividends in recent years. Based on the key indicators related to SAB Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, SAB Biotherapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.SAB Biotherapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. SAB Biotherapeutics has an asset utilization ratio of 2.67 percent. This indicates that the Company is making $0.0267 for each dollar of assets. An increasing asset utilization means that SAB Biotherapeutics is more efficient with each dollar of assets it utilizes for everyday operations.SAB Biotherapeutics Profitability Analysis
The company reported the revenue of 2.24 M. Net Loss for the year was (42.19 M) with loss before overhead, payroll, taxes, and interest of (25.38 M).About SAB Biotherapeutics Valuation
Our relative valuation model uses a comparative analysis of SAB Biotherapeutics. We calculate exposure to SAB Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of SAB Biotherapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.4 M | -1.3 M | |
| Pretax Profit Margin | (21.67) | (20.59) | |
| Operating Profit Margin | (19.56) | (18.58) | |
| Net Loss | (21.67) | (20.59) | |
| Gross Profit Margin | (0.77) | (0.73) |
SAB Biotherapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as SAB Biotherapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 5.5 M |
SAB Biotherapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of SAB Biotherapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value SAB we look at many different elements of the entity such as SAB's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as SAB Biotherapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use SAB Biotherapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes SAB Biotherapeutics' worth.Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.